Search Genes

GET /api/v1/genes/?format=api&page=286
HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 35521,
    "next": "https://panelapp-aus.org/api/v1/genes/?format=api&page=287",
    "previous": "https://panelapp-aus.org/api/v1/genes/?format=api&page=285",
    "results": [
        {
            "gene_data": {
                "alias": [
                    "MGC39558"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28596",
                "gene_name": "beta-1,3-N-acetylgalactosaminyltransferase 2",
                "omim_gene": [
                    "610194"
                ],
                "alias_name": null,
                "gene_symbol": "B3GALNT2",
                "hgnc_symbol": "B3GALNT2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:235613238-235667781",
                            "ensembl_id": "ENSG00000162885"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:235449923-235504481",
                            "ensembl_id": "ENSG00000162885"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-02-10"
            },
            "entity_type": "gene",
            "entity_name": "B3GALNT2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23453667",
                "33290285",
                "29791932",
                "29273094",
                "28688748",
                "28303321"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, MIM# 615181",
                "MONDO:0014071"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "iGNT",
                    "iGAT",
                    "iGnT",
                    "BETA3GNTI",
                    "B3GN-T1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:15685",
                "gene_name": "beta-1,4-glucuronyltransferase 1",
                "omim_gene": [
                    "605517"
                ],
                "alias_name": [
                    "N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase"
                ],
                "gene_symbol": "B4GAT1",
                "hgnc_symbol": "B4GAT1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:66112843-66115163",
                            "ensembl_id": "ENSG00000174684"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:66345372-66347692",
                            "ensembl_id": "ENSG00000174684"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2014-12-17"
            },
            "entity_type": "gene",
            "entity_name": "B4GAT1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23359570",
                "23877401",
                "23359570",
                "23217742"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "B9",
                    "EPPB9",
                    "MKS9"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24123",
                "gene_name": "B9 domain containing 1",
                "omim_gene": [
                    "614144"
                ],
                "alias_name": [
                    "endothelial precursor protein B9"
                ],
                "gene_symbol": "B9D1",
                "hgnc_symbol": "B9D1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:19240867-19281495",
                            "ensembl_id": "ENSG00000108641"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:19337554-19378182",
                            "ensembl_id": "ENSG00000108641"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-08-21"
            },
            "entity_type": "gene",
            "entity_name": "B9D1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32622957",
                "24886560",
                "21493627",
                "25920555",
                "34338422",
                "21763481"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Ciliopathy, MONDO:0005308, B9D1-related"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC4093",
                    "MKS10"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28636",
                "gene_name": "B9 domain containing 2",
                "omim_gene": [
                    "611951"
                ],
                "alias_name": null,
                "gene_symbol": "B9D2",
                "hgnc_symbol": "B9D2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:41860326-41870078",
                            "ensembl_id": "ENSG00000123810"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:41354421-41364173",
                            "ensembl_id": "ENSG00000123810"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-08-21"
            },
            "entity_type": "gene",
            "entity_name": "B9D2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21763481",
                "31411728",
                "26092869"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Joubert syndrome 34, OMIM:614175",
                "Meckel syndrome 10, OMIM:614175",
                "Meckel syndrome, type 10, MONDO:0013609"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "BAF"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:17397",
                "gene_name": "barrier to autointegration factor 1",
                "omim_gene": [
                    "603811"
                ],
                "alias_name": null,
                "gene_symbol": "BANF1",
                "hgnc_symbol": "BANF1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:65769550-65771620",
                            "ensembl_id": "ENSG00000175334"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:66002079-66004149",
                            "ensembl_id": "ENSG00000175334"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-02-14"
            },
            "entity_type": "gene",
            "entity_name": "BANF1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32783369",
                "21549337"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Nestor-Guillermo progeria syndrome, MIM# 614008"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DLNB11"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23688",
                "gene_name": "B-cell CLL/lymphoma 9 like",
                "omim_gene": [
                    "609004"
                ],
                "alias_name": null,
                "gene_symbol": "BCL9L",
                "hgnc_symbol": "BCL9L",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:118764584-118796317",
                            "ensembl_id": "ENSG00000186174"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:118893875-118925608",
                            "ensembl_id": "ENSG00000186174"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-12-09"
            },
            "entity_type": "gene",
            "entity_name": "BCL9L",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23035047",
                "8757136",
                "30366904"
            ],
            "evidence": [
                "Expert Review Amber",
                "Other",
                "Literature",
                "Expert list",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Heterotaxy",
                "Congenital Heart Disease"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HPS9"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8549",
                "gene_name": "biogenesis of lysosomal organelles complex 1 subunit 6",
                "omim_gene": [
                    "604310"
                ],
                "alias_name": null,
                "gene_symbol": "BLOC1S6",
                "hgnc_symbol": "BLOC1S6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:45879321-45908197",
                            "ensembl_id": "ENSG00000104164"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:45587123-45615999",
                            "ensembl_id": "ENSG00000104164"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2012-08-01"
            },
            "entity_type": "gene",
            "entity_name": "BLOC1S6",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22461475",
                "21665000",
                "32245340"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hermansky-Pudlak syndrome 9, MIM# 614171"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "BSN2",
                    "FLJ20043"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30988",
                "gene_name": "basonuclin 2",
                "omim_gene": [
                    "608669"
                ],
                "alias_name": null,
                "gene_symbol": "BNC2",
                "hgnc_symbol": "BNC2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:16409501-16870841",
                            "ensembl_id": "ENSG00000173068"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:16409503-16870843",
                            "ensembl_id": "ENSG00000173068"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-04-29"
            },
            "entity_type": "gene",
            "entity_name": "BNC2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31656805",
                "31051115"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Lower urinary tract obstruction, congenital, MIM #618612"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24415",
                "gene_name": "bolA family member 3",
                "omim_gene": [
                    "613183"
                ],
                "alias_name": null,
                "gene_symbol": "BOLA3",
                "hgnc_symbol": "BOLA3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:74362525-74375121",
                            "ensembl_id": "ENSG00000163170"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:74135398-74147994",
                            "ensembl_id": "ENSG00000163170"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-05-09"
            },
            "entity_type": "gene",
            "entity_name": "BOLA3",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30302924",
                "29654549",
                "30302924"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, MIM# 614299"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FAC1",
                    "NURF301"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3581",
                "gene_name": "bromodomain PHD finger transcription factor",
                "omim_gene": [
                    "601819"
                ],
                "alias_name": null,
                "gene_symbol": "BPTF",
                "hgnc_symbol": "BPTF",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:65821640-65980494",
                            "ensembl_id": "ENSG00000171634"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:67825524-67984378",
                            "ensembl_id": "ENSG00000171634"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-12-01"
            },
            "entity_type": "gene",
            "entity_name": "BPTF",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28942966",
                "33522091"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies AD, MIM#617755"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GRCC10",
                    "C10"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29521",
                "gene_name": "chromosome 12 open reading frame 57",
                "omim_gene": [
                    "615140"
                ],
                "alias_name": [
                    "gene rich cluster C10 gene"
                ],
                "gene_symbol": "C12orf57",
                "hgnc_symbol": "C12orf57",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:7052141-7055166",
                            "ensembl_id": "ENSG00000111678"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:6942978-6946003",
                            "ensembl_id": "ENSG00000111678"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-01-27"
            },
            "entity_type": "gene",
            "entity_name": "C12orf57",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Temtamy syndrome, MIM#218340"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "gC1Q-R",
                    "gC1qR",
                    "p32",
                    "SF2p32"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1243",
                "gene_name": "complement C1q binding protein",
                "omim_gene": [
                    "601269"
                ],
                "alias_name": [
                    "C1q globular domain-binding protein",
                    "hyaluronan-binding protein 1",
                    "splicing factor SF2-associated protein"
                ],
                "gene_symbol": "C1QBP",
                "hgnc_symbol": "C1QBP",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:5336097-5352150",
                            "ensembl_id": "ENSG00000108561"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:5432777-5448830",
                            "ensembl_id": "ENSG00000108561"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-12-11"
            },
            "entity_type": "gene",
            "entity_name": "C1QBP",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28942965"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Combined oxidative phosphorylation deficiency 33, MIM# 617713",
                "severe neonatal cardiomyopathy"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ20467",
                    "FBB18",
                    "CILD26",
                    "Kur"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1301",
                "gene_name": "chromosome 21 open reading frame 59",
                "omim_gene": [
                    "615494"
                ],
                "alias_name": [
                    "kurly homolog (zebrafish)"
                ],
                "gene_symbol": "C21orf59",
                "hgnc_symbol": "C21orf59",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "21:33964389-33985176",
                            "ensembl_id": "ENSG00000159079"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "21:32592079-32612866",
                            "ensembl_id": "ENSG00000159079"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-06-28"
            },
            "entity_type": "gene",
            "entity_name": "C21orf59",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24094744"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Primary ciliary dyskinesia 26, MONDO:0014211",
                "Ciliary dyskinesia, primary, 26, OMIM:615500"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "founder",
                "new gene name"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DKFZP586P0123"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24564",
                "gene_name": "C2 calcium dependent domain containing 3",
                "omim_gene": [
                    "615944"
                ],
                "alias_name": null,
                "gene_symbol": "C2CD3",
                "hgnc_symbol": "C2CD3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:73723763-73882255",
                            "ensembl_id": "ENSG00000168014"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:74012714-74171210",
                            "ensembl_id": "ENSG00000168014"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-10-17"
            },
            "entity_type": "gene",
            "entity_name": "C2CD3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24997988",
                "26477546",
                "27094867",
                "30097616",
                "33875766"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list",
                "Victorian Clinical Genetics Services",
                "Victorian Clinical Genetics Services",
                "Melbourne Genomics Health Alliance Perinatal Autopsy Flagship"
            ],
            "phenotypes": [
                "Orofaciodigital syndrome XIV, MIM# 615948",
                "MONDO:0014413"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CAV",
                    "CAVA"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1377",
                "gene_name": "carbonic anhydrase 5A",
                "omim_gene": [
                    "114761"
                ],
                "alias_name": null,
                "gene_symbol": "CA5A",
                "hgnc_symbol": "CA5A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:87921625-87970135",
                            "ensembl_id": "ENSG00000174990"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:87881546-87936529",
                            "ensembl_id": "ENSG00000174990"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-10-15"
            },
            "entity_type": "gene",
            "entity_name": "CA5A",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "26913920"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Hyperammonemia due to carbonic anhydrase VA deficiency, MIM# 615751"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Cav2.1",
                    "EA2",
                    "APCA",
                    "HPCA",
                    "FHM"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1388",
                "gene_name": "calcium voltage-gated channel subunit alpha1 A",
                "omim_gene": [
                    "601011"
                ],
                "alias_name": null,
                "gene_symbol": "CACNA1A",
                "hgnc_symbol": "CACNA1A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:13317256-13734804",
                            "ensembl_id": "ENSG00000141837"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:13206442-13633025",
                            "ensembl_id": "ENSG00000141837"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1996-06-18"
            },
            "entity_type": "gene",
            "entity_name": "CACNA1A",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Developemental and epileptic encephalopathy 42, MIM# 617106",
                "Episodic ataxia, type 2, MIM# 108500",
                "Migraine, familial hemiplegic, 1, MIM# 141500",
                "Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia 141500",
                "Spinocerebellar ataxia 6, MIM# 183086"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Cav1.3",
                    "CACH3",
                    "CACN4"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1391",
                "gene_name": "calcium voltage-gated channel subunit alpha1 D",
                "omim_gene": [
                    "114206"
                ],
                "alias_name": null,
                "gene_symbol": "CACNA1D",
                "hgnc_symbol": "CACNA1D",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:53528683-53847760",
                            "ensembl_id": "ENSG00000157388"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:53328963-53813733",
                            "ensembl_id": "ENSG00000157388"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1991-12-12"
            },
            "entity_type": "gene",
            "entity_name": "CACNA1D",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "31921405",
                "28472301",
                "25620733"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Primary aldosteronism, seizures, and neurologic abnormalities, MIM# 615474"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Cav3.1",
                    "NBR13"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1394",
                "gene_name": "calcium voltage-gated channel subunit alpha1 G",
                "omim_gene": [
                    "604065"
                ],
                "alias_name": null,
                "gene_symbol": "CACNA1G",
                "hgnc_symbol": "CACNA1G",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:48638429-48704835",
                            "ensembl_id": "ENSG00000006283"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:50561068-50627474",
                            "ensembl_id": "ENSG00000006283"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-01-08"
            },
            "entity_type": "gene",
            "entity_name": "CACNA1G",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "29878067",
                "31836334"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits, 618087"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0968",
                    "CaMKIINalpha"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1460",
                "gene_name": "calcium/calmodulin dependent protein kinase II alpha",
                "omim_gene": [
                    "114078"
                ],
                "alias_name": [
                    "CaM-kinase II alpha chain",
                    "calcium/calmodulin-dependent protein kinase II alpha-B subunit",
                    "CaM kinase II alpha subunit",
                    "CaMK-II alpha subunit",
                    "calcium/calmodulin-dependent protein kinase type II alpha chain"
                ],
                "gene_symbol": "CAMK2A",
                "hgnc_symbol": "CAMK2A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:149599054-149669854",
                            "ensembl_id": "ENSG00000070808"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:150219491-150290291",
                            "ensembl_id": "ENSG00000070808"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-11-24"
            },
            "entity_type": "gene",
            "entity_name": "CAMK2A",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32600977",
                "29784083",
                "29560374"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Mental retardation, autosomal recessive 63 MIM#618095",
                "Mental retardation, autosomal dominant 53 MIM#617798"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CAM2",
                    "CAMK2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1461",
                "gene_name": "calcium/calmodulin dependent protein kinase II beta",
                "omim_gene": [
                    "607707"
                ],
                "alias_name": [
                    "CaM-kinase II beta chain",
                    "calcium/calmodulin-dependent protein kinase type II beta chain",
                    "CaM kinase II beta subunit",
                    "proline rich calmodulin-dependent protein kinase"
                ],
                "gene_symbol": "CAMK2B",
                "hgnc_symbol": "CAMK2B",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:44256749-44374176",
                            "ensembl_id": "ENSG00000058404"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:44217150-44334577",
                            "ensembl_id": "ENSG00000058404"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1993-11-24"
            },
            "entity_type": "gene",
            "entity_name": "CAMK2B",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29100089",
                "29560374",
                "32875707"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Literature",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, autosomal dominant 54, MIM# 617799"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0833"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18806",
                "gene_name": "calmodulin binding transcription activator 1",
                "omim_gene": [
                    "611501"
                ],
                "alias_name": null,
                "gene_symbol": "CAMTA1",
                "hgnc_symbol": "CAMTA1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:6845384-7829766",
                            "ensembl_id": "ENSG00000171735"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:6785324-7769706",
                            "ensembl_id": "ENSG00000171735"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-06-20"
            },
            "entity_type": "gene",
            "entity_name": "CAMTA1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32157189",
                "22693284"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Cerebellar ataxia, nonprogressive, with mental retardation (614756 AD)"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SHAPY",
                    "SCAN-1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19721",
                "gene_name": "calcium activated nucleotidase 1",
                "omim_gene": [
                    "613165"
                ],
                "alias_name": [
                    "Soluble Ca-Activated Nucleotidase, isozyme 1"
                ],
                "gene_symbol": "CANT1",
                "hgnc_symbol": "CANT1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:76987799-77005949",
                            "ensembl_id": "ENSG00000171302"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:78991717-79009867",
                            "ensembl_id": "ENSG00000171302"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-10-15"
            },
            "entity_type": "gene",
            "entity_name": "CANT1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Desbuquois dysplasia 1, MIM# 251450"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ12118"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:25695",
                "gene_name": "cysteinyl-tRNA synthetase 2, mitochondrial",
                "omim_gene": [
                    "612800"
                ],
                "alias_name": [
                    "cysteine tRNA ligase 2, mitochondrial (putative)"
                ],
                "gene_symbol": "CARS2",
                "hgnc_symbol": "CARS2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "13:111293759-111365950",
                            "ensembl_id": "ENSG00000134905"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "13:110641412-110713603",
                            "ensembl_id": "ENSG00000134905"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-01-24"
            },
            "entity_type": "gene",
            "entity_name": "CARS2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30139652",
                "25787132"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Combined oxidative phosphorylation deficiency 27, MIM#616672"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FHH",
                    "NSHPT",
                    "GPRC2A"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1514",
                "gene_name": "calcium sensing receptor",
                "omim_gene": [
                    "601199"
                ],
                "alias_name": [
                    "severe neonatal hyperparathyroidism"
                ],
                "gene_symbol": "CASR",
                "hgnc_symbol": "CASR",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:121902530-122005342",
                            "ensembl_id": "ENSG00000036828"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:122183683-122291629",
                            "ensembl_id": "ENSG00000036828"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-12-04"
            },
            "entity_type": "gene",
            "entity_name": "CASR",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Hyperparathyroidism, neonatal, MIM# 239200"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC20983"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28303",
                "gene_name": "coiled-coil domain containing 151",
                "omim_gene": [
                    "615956"
                ],
                "alias_name": null,
                "gene_symbol": "CCDC151",
                "hgnc_symbol": "CCDC151",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:11531272-11546603",
                            "ensembl_id": "ENSG00000198003"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:11420604-11435782",
                            "ensembl_id": "ENSG00000198003"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2008-04-10"
            },
            "entity_type": "gene",
            "entity_name": "CCDC151",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25192045",
                "25224326",
                "32490514",
                "32286033",
                "30504913"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Primary ciliary dyskinesia 30, MONDO:0014465",
                "Ciliary dyskinesia, primary, 30, OMIM:616037"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "new gene name"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "JM1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28909",
                "gene_name": "coiled-coil domain containing 22",
                "omim_gene": [
                    "300859"
                ],
                "alias_name": null,
                "gene_symbol": "CCDC22",
                "hgnc_symbol": "CCDC22",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:49091927-49106987",
                            "ensembl_id": "ENSG00000101997"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:49235467-49250526",
                            "ensembl_id": "ENSG00000101997"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-07-24"
            },
            "entity_type": "gene",
            "entity_name": "CCDC22",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21826058",
                "24916641",
                "34020006",
                "33059814",
                "31971710"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ritscher-Schinzel syndrome 2, MIM# 300963"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, biallelic mutations in females",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ34512"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14153",
                "gene_name": "coiled-coil domain containing 78",
                "omim_gene": [
                    "614666"
                ],
                "alias_name": null,
                "gene_symbol": "CCDC78",
                "hgnc_symbol": "CCDC78",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:772582-776954",
                            "ensembl_id": "ENSG00000162004"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:722582-726954",
                            "ensembl_id": "ENSG00000162004"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-02-20"
            },
            "entity_type": "gene",
            "entity_name": "CCDC78",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22818856"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Centronuclear myopathy 4, MIM#614807"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DKFZp564K0322",
                    "3M3",
                    "PPP1R20"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:25367",
                "gene_name": "coiled-coil domain containing 8",
                "omim_gene": [
                    "614145"
                ],
                "alias_name": [
                    "protein phosphatase 1, regulatory subunit 20"
                ],
                "gene_symbol": "CCDC8",
                "hgnc_symbol": "CCDC8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:46913629-46916841",
                            "ensembl_id": "ENSG00000169515"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:46410372-46413584",
                            "ensembl_id": "ENSG00000169515"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-02-11"
            },
            "entity_type": "gene",
            "entity_name": "CCDC8",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21737058"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "3M syndrome 3, MONDO:0013627",
                "3-M syndrome 3, OMIM:614205"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DAPLE",
                    "HkRP2",
                    "SCA40"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19967",
                "gene_name": "coiled-coil domain containing 88C",
                "omim_gene": [
                    "611204"
                ],
                "alias_name": [
                    "Dvl-associating protein with a high frequency of leucine residues",
                    "spinocerebellar ataxia 40"
                ],
                "gene_symbol": "CCDC88C",
                "hgnc_symbol": "CCDC88C",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:91737667-91884188",
                            "ensembl_id": "ENSG00000015133"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:91271323-91417844",
                            "ensembl_id": "ENSG00000015133"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-05-31"
            },
            "entity_type": "gene",
            "entity_name": "CCDC88C",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23042809",
                "21031079"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Hydrocephalus, nonsyndromic, autosomal recessive 1, MONDO:0009360",
                "Hydrocephalus, congenital, 1, OMIM:236600"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "SFA-1",
                    "PETA-3",
                    "TSPAN24",
                    "RAPH"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1630",
                "gene_name": "CD151 molecule (Raph blood group)",
                "omim_gene": [
                    "602243"
                ],
                "alias_name": null,
                "gene_symbol": "CD151",
                "hgnc_symbol": "CD151",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:832843-839831",
                            "ensembl_id": "ENSG00000177697"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:832843-839831",
                            "ensembl_id": "ENSG00000177697"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1997-04-10"
            },
            "entity_type": "gene",
            "entity_name": "CD151",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "15265795",
                "29138120"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Nephropathy with pretibial epidermolysis bullosa and deafness, MIM#609057"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "TACTILE"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:16892",
                "gene_name": "CD96 molecule",
                "omim_gene": [
                    "606037"
                ],
                "alias_name": null,
                "gene_symbol": "CD96",
                "hgnc_symbol": "CD96",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:111011566-111384597",
                            "ensembl_id": "ENSG00000153283"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:111292719-111665750",
                            "ensembl_id": "ENSG00000153283"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-01-22"
            },
            "entity_type": "gene",
            "entity_name": "CD96",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "17847009"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "C syndrome, MIM#211750"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "C48",
                    "FLJ10867",
                    "CEP215"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18672",
                "gene_name": "CDK5 regulatory subunit associated protein 2",
                "omim_gene": [
                    "608201"
                ],
                "alias_name": [
                    "centrosomin"
                ],
                "gene_symbol": "CDK5RAP2",
                "hgnc_symbol": "CDK5RAP2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:123151147-123342448",
                            "ensembl_id": "ENSG00000136861"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:120388869-120580170",
                            "ensembl_id": "ENSG00000136861"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-07-22"
            },
            "entity_type": "gene",
            "entity_name": "CDK5RAP2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "15793586",
                "22887808",
                "23995685",
                "23726037",
                "27761245",
                "20460369",
                "32677750",
                "32015000"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Microcephaly 3, primary, autosomal recessive, MONDO:0011488",
                "Microcephaly 3, primary, autosomal recessive, OMIM:604804"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ME2",
                    "HFMI2",
                    "FMI2",
                    "CDHF9",
                    "ADGRC1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1850",
                "gene_name": "cadherin EGF LAG seven-pass G-type receptor 1",
                "omim_gene": [
                    "604523"
                ],
                "alias_name": [
                    "flamingo homolog 2 (Drosophila)",
                    "adhesion G protein-coupled receptor C1"
                ],
                "gene_symbol": "CELSR1",
                "hgnc_symbol": "CELSR1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "22:46756731-46933067",
                            "ensembl_id": "ENSG00000075275"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "22:46360834-46537170",
                            "ensembl_id": "ENSG00000075275"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-02-14"
            },
            "entity_type": "gene",
            "entity_name": "CELSR1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31215153",
                "31403174",
                "26855770",
                "38272662"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Lymphatic malformation 9, MIM# 619319"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "hcp-1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1857",
                "gene_name": "centromere protein F",
                "omim_gene": [
                    "600236"
                ],
                "alias_name": [
                    "mitosin"
                ],
                "gene_symbol": "CENPF",
                "hgnc_symbol": "CENPF",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:214776538-214837931",
                            "ensembl_id": "ENSG00000117724"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:214603195-214664588",
                            "ensembl_id": "ENSG00000117724"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-07-04"
            },
            "entity_type": "gene",
            "entity_name": "CENPF",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25564561",
                "28407396",
                "26820108"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature",
                "Expert Review"
            ],
            "phenotypes": [
                "Stromme syndrome, MIM#243605"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ13621"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:29086",
                "gene_name": "centrosomal protein 135",
                "omim_gene": [
                    "611423"
                ],
                "alias_name": null,
                "gene_symbol": "CEP135",
                "hgnc_symbol": "CEP135",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "4:56815037-56899529",
                            "ensembl_id": "ENSG00000174799"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "4:55948871-56033363",
                            "ensembl_id": "ENSG00000174799"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-12-02"
            },
            "entity_type": "gene",
            "entity_name": "CEP135",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30214071",
                "22521416",
                "26657937"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Microcephaly 8, primary, autosomal recessive, OMIM:614673",
                "Microcephaly 8, primary, autosomal recessive, MONDO:0013849",
                "Microcephalic primordial dwarfism"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ10540",
                    "CT111"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1161",
                "gene_name": "centrosomal protein 55",
                "omim_gene": [
                    "610000"
                ],
                "alias_name": [
                    "cancer/testis antigen 111"
                ],
                "gene_symbol": "CEP55",
                "hgnc_symbol": "CEP55",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:95256389-95288849",
                            "ensembl_id": "ENSG00000138180"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:93496632-93529092",
                            "ensembl_id": "ENSG00000138180"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-12-01"
            },
            "entity_type": "gene",
            "entity_name": "CEP55",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28295209",
                "28264986",
                "30622327",
                "32100459"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500",
                "lethal CEP55-related syndromes"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ13386"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:25815",
                "gene_name": "centrosomal protein 63",
                "omim_gene": [
                    "614724"
                ],
                "alias_name": null,
                "gene_symbol": "CEP63",
                "hgnc_symbol": "CEP63",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:134204585-134293859",
                            "ensembl_id": "ENSG00000182923"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:134485743-134575017",
                            "ensembl_id": "ENSG00000182923"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-12-01"
            },
            "entity_type": "gene",
            "entity_name": "CEP63",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21983783",
                "26158450"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Seckel syndrome 6, OMIM:614728",
                "Seckel syndrome 6, MONDO:0013871"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC27091"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23752",
                "gene_name": "ceramide synthase 3",
                "omim_gene": [
                    "615276"
                ],
                "alias_name": null,
                "gene_symbol": "CERS3",
                "hgnc_symbol": "CERS3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:100940600-101085200",
                            "ensembl_id": "ENSG00000154227"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:100400395-100544995",
                            "ensembl_id": "ENSG00000154227"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2011-07-08"
            },
            "entity_type": "gene",
            "entity_name": "CERS3",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23754960",
                "23549421",
                "31168818",
                "30578701"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ichthyosis, congenital, autosomal recessive 9, MIM# 615023"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "NEM7"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1875",
                "gene_name": "cofilin 2",
                "omim_gene": [
                    "601443"
                ],
                "alias_name": [
                    "nemaline myopathy type 7"
                ],
                "gene_symbol": "CFL2",
                "hgnc_symbol": "CFL2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:35179593-35184029",
                            "ensembl_id": "ENSG00000165410"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:34706769-34714823",
                            "ensembl_id": "ENSG00000165410"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-07-11"
            },
            "entity_type": "gene",
            "entity_name": "CFL2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "17160903",
                "22560515",
                "32697999",
                "29457652",
                "24610938"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Nemaline myopathy 7, MONDO:0012538",
                "Nemaline myopathy 7, autosomal recessive, OMIM:610687"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Mi-2a",
                    "ZFH",
                    "Mi2-ALPHA"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1918",
                "gene_name": "chromodomain helicase DNA binding protein 3",
                "omim_gene": [
                    "602120"
                ],
                "alias_name": null,
                "gene_symbol": "CHD3",
                "hgnc_symbol": "CHD3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:7788124-7816078",
                            "ensembl_id": "ENSG00000170004"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:7884806-7912760",
                            "ensembl_id": "ENSG00000170004"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-03-20"
            },
            "entity_type": "gene",
            "entity_name": "CHD3",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "30397230"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Snijders Blok-Campeau syndrome, MIM#618205"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA1564",
                    "DUPLIN"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20153",
                "gene_name": "chromodomain helicase DNA binding protein 8",
                "omim_gene": [
                    "610528"
                ],
                "alias_name": null,
                "gene_symbol": "CHD8",
                "hgnc_symbol": "CHD8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:21853353-21924285",
                            "ensembl_id": "ENSG00000100888"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:21385194-21456126",
                            "ensembl_id": "ENSG00000100888"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-06-23"
            },
            "entity_type": "gene",
            "entity_name": "CHD8",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31980904"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "{Autism, susceptibility to, 18} 615032",
                "CHD8-related neurodevelopmental syndrome"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0047",
                    "CHMP1",
                    "Vps46A"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:8740",
                "gene_name": "charged multivesicular body protein 1A",
                "omim_gene": [
                    "164010"
                ],
                "alias_name": null,
                "gene_symbol": "CHMP1A",
                "hgnc_symbol": "CHMP1A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:89710839-89724253",
                            "ensembl_id": "ENSG00000131165"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:89644431-89657845",
                            "ensembl_id": "ENSG00000131165"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-03-20"
            },
            "entity_type": "gene",
            "entity_name": "CHMP1A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23023333"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Pontocerebellar hypoplasia type 8, MONDO:0013990",
                "Pontocerebellar hypoplasia, type 8, OMIM:614961"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1957",
                "gene_name": "cholinergic receptor nicotinic alpha 3 subunit",
                "omim_gene": [
                    "118503"
                ],
                "alias_name": [
                    "acetylcholine receptor, nicotinic, alpha 3 (neuronal)"
                ],
                "gene_symbol": "CHRNA3",
                "hgnc_symbol": "CHRNA3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "15:78885394-78913637",
                            "ensembl_id": "ENSG00000080644"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "15:78593052-78621295",
                            "ensembl_id": "ENSG00000080644"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1990-05-11"
            },
            "entity_type": "gene",
            "entity_name": "CHRNA3",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31708116"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Bladder dysfunction, autonomic, with impaired pupillary reflex and secondary CAKUT, MIM# 191800"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1961",
                "gene_name": "cholinergic receptor nicotinic beta 1 subunit",
                "omim_gene": [
                    "100710"
                ],
                "alias_name": [
                    "acetylcholine receptor, nicotinic, beta 1 (muscle)"
                ],
                "gene_symbol": "CHRNB1",
                "hgnc_symbol": "CHRNB1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:7348380-7361026",
                            "ensembl_id": "ENSG00000170175"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:7445061-7457707",
                            "ensembl_id": "ENSG00000170175"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1989-05-25"
            },
            "entity_type": "gene",
            "entity_name": "CHRNB1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "8872460",
                "8651643",
                "27375219",
                "32504635",
                "10562302"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Myasthenic syndrome, slow-channel congenital, 601462 Myasthenic syndrome, congenital, 2A, slow-channel, 616313",
                "Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency, 616314"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ACHRE"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1966",
                "gene_name": "cholinergic receptor nicotinic epsilon subunit",
                "omim_gene": [
                    "100725"
                ],
                "alias_name": [
                    "acetylcholine receptor, nicotinic, epsilon (muscle)"
                ],
                "gene_symbol": "CHRNE",
                "hgnc_symbol": "CHRNE",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:4801069-4806369",
                            "ensembl_id": "ENSG00000108556"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:4897774-4903074",
                            "ensembl_id": "ENSG00000108556"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-04-23"
            },
            "entity_type": "gene",
            "entity_name": "CHRNE",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Myasthenic syndrome, congenital, 4A, slow-channel, 605809",
                "Myasthenic syndrome, congenital, 4B, fast-channel, 616324",
                "Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0949",
                    "STK21",
                    "CRIK",
                    "CITK"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:1985",
                "gene_name": "citron rho-interacting serine/threonine kinase",
                "omim_gene": [
                    "605629"
                ],
                "alias_name": [
                    "serine/threonine kinase 21"
                ],
                "gene_symbol": "CIT",
                "hgnc_symbol": "CIT",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:120123595-120315095",
                            "ensembl_id": "ENSG00000122966"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:119685790-119877291",
                            "ensembl_id": "ENSG00000122966"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-08-05"
            },
            "entity_type": "gene",
            "entity_name": "CIT",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27453578",
                "27503289",
                "27453579"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Microcephaly 17, primary, autosomal recessive, OMIM:617090",
                "Microcephaly 17, primary, autosomal recessive, MONDO:0014908"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "hClC-Kb"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2027",
                "gene_name": "chloride voltage-gated channel Kb",
                "omim_gene": [
                    "602023"
                ],
                "alias_name": null,
                "gene_symbol": "CLCNKB",
                "hgnc_symbol": "CLCNKB",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:16370272-16383803",
                            "ensembl_id": "ENSG00000184908"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:16043736-16057308",
                            "ensembl_id": "ENSG00000184908"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-12-11"
            },
            "entity_type": "gene",
            "entity_name": "CLCNKB",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "18310267",
                "29254190"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Bartter syndrome, type 3, MIM#607364",
                "Bartter syndrome, type 4b, digenic, MIM#613090"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ASAM",
                    "FLJ22415",
                    "ACAM"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:24039",
                "gene_name": "CXADR like membrane protein",
                "omim_gene": [
                    "611693"
                ],
                "alias_name": [
                    "adipocyte-specific adhesion molecule",
                    "coxsackie- and adenovirus receptor-like membrane protein",
                    "adipocyte adhesion molecule"
                ],
                "gene_symbol": "CLMP",
                "hgnc_symbol": "CLMP",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:122943035-123065989",
                            "ensembl_id": "ENSG00000166250"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:123069865-123195281",
                            "ensembl_id": "ENSG00000166250"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2011-01-27"
            },
            "entity_type": "gene",
            "entity_name": "CLMP",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22155368"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Congenital short bowel syndrome , MIM#615237"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HEAB",
                    "hClp1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:16999",
                "gene_name": "cleavage and polyadenylation factor I subunit 1",
                "omim_gene": [
                    "608757"
                ],
                "alias_name": [
                    "ATP/GTPbinding protein",
                    "polyribonucleotide 5'-hydroxyl-kinase"
                ],
                "gene_symbol": "CLP1",
                "hgnc_symbol": "CLP1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:57416465-57429340",
                            "ensembl_id": "ENSG00000172409"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:57648992-57661868",
                            "ensembl_id": "ENSG00000172409"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-11-13"
            },
            "entity_type": "gene",
            "entity_name": "CLP1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24766809",
                "29307788"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Pontocerebellar hypoplasia, type 10, OMIM:615803",
                "Pontocerebellar hypoplasia type 10, MONDO:0014349"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2084",
                "gene_name": "caseinolytic mitochondrial matrix peptidase proteolytic subunit",
                "omim_gene": [
                    "601119"
                ],
                "alias_name": [
                    "ATP-dependent protease ClpAP (E. coli), proteolytic subunit, human"
                ],
                "gene_symbol": "CLPP",
                "hgnc_symbol": "CLPP",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:6361463-6368919",
                            "ensembl_id": "ENSG00000125656"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:6361452-6368908",
                            "ensembl_id": "ENSG00000125656"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-09-20"
            },
            "entity_type": "gene",
            "entity_name": "CLPP",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23541340"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Perrault syndrome 3, MIM# 614129"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "Hc"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2092",
                "gene_name": "clathrin heavy chain",
                "omim_gene": [
                    "118955"
                ],
                "alias_name": null,
                "gene_symbol": "CLTC",
                "hgnc_symbol": "CLTC",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:57697219-57773671",
                            "ensembl_id": "ENSG00000141367"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:59619689-59696956",
                            "ensembl_id": "ENSG00000141367"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1990-10-16"
            },
            "entity_type": "gene",
            "entity_name": "CLTC",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "33743358",
                "29100083",
                "26822784",
                "34230591",
                "31776469"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, autosomal dominant 56, MIM# 617854"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RNF163",
                    "ZCCHC22",
                    "CNBP1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:13164",
                "gene_name": "CCHC-type zinc finger nucleic acid binding protein",
                "omim_gene": [
                    "116955"
                ],
                "alias_name": null,
                "gene_symbol": "CNBP",
                "hgnc_symbol": "CNBP",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:128888327-128902765",
                            "ensembl_id": "ENSG00000169714"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:129169484-129183922",
                            "ensembl_id": "ENSG00000169714"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-06-29"
            },
            "entity_type": "gene",
            "entity_name": "CNBP",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Myotonic dystrophy 2, MIM#602668"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [
                "STR"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0902",
                    "CNK2",
                    "KSR2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19701",
                "gene_name": "connector enhancer of kinase suppressor of Ras 2",
                "omim_gene": [
                    "300724"
                ],
                "alias_name": null,
                "gene_symbol": "CNKSR2",
                "hgnc_symbol": "CNKSR2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "X:21392536-21672813",
                            "ensembl_id": "ENSG00000149970"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "X:21374418-21654695",
                            "ensembl_id": "ENSG00000149970"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-05-27"
            },
            "entity_type": "gene",
            "entity_name": "CNKSR2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "34266427"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Intellectual developmental disorder, X-linked, syndromic, Houge type, MIM# 301008"
            ],
            "mode_of_inheritance": "X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males)",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "F3",
                    "GP135"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2171",
                "gene_name": "contactin 1",
                "omim_gene": [
                    "600016"
                ],
                "alias_name": [
                    "glycoprotein gP135"
                ],
                "gene_symbol": "CNTN1",
                "hgnc_symbol": "CNTN1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:41086244-41466220",
                            "ensembl_id": "ENSG00000018236"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:40692442-41072418",
                            "ensembl_id": "ENSG00000018236"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-02-18"
            },
            "entity_type": "gene",
            "entity_name": "CNTN1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32779773",
                "19026398"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Myopathy, congenital, Compton-North, OMIM:612540"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "GTC90"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14857",
                "gene_name": "component of oligomeric golgi complex 5",
                "omim_gene": [
                    "606821"
                ],
                "alias_name": null,
                "gene_symbol": "COG5",
                "hgnc_symbol": "COG5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:106842000-107204959",
                            "ensembl_id": "ENSG00000164597"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:107201555-107564514",
                            "ensembl_id": "ENSG00000164597"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-05-10"
            },
            "entity_type": "gene",
            "entity_name": "COG5",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23228021",
                "31572517",
                "32174980"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "COG5-CDG, MONDO:0013325",
                "Congenital disorder of glycosylation, type III, OMIM:613612"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "COD2",
                    "KIAA1134"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18621",
                "gene_name": "component of oligomeric golgi complex 6",
                "omim_gene": [
                    "606977"
                ],
                "alias_name": null,
                "gene_symbol": "COG6",
                "hgnc_symbol": "COG6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "13:40229764-40365802",
                            "ensembl_id": "ENSG00000133103"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "13:39655627-39791665",
                            "ensembl_id": "ENSG00000133103"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-05-09"
            },
            "entity_type": "gene",
            "entity_name": "COG6",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Congenital disorder of glycosylation, type IIl, 614576",
                "Shaheen syndrome, 615328"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2188",
                "gene_name": "collagen type XII alpha 1 chain",
                "omim_gene": [
                    "120320"
                ],
                "alias_name": [
                    "collagen type XII proteoglycan"
                ],
                "gene_symbol": "COL12A1",
                "hgnc_symbol": "COL12A1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:75794042-75915767",
                            "ensembl_id": "ENSG00000111799"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:75084326-75206051",
                            "ensembl_id": "ENSG00000111799"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-03-24"
            },
            "entity_type": "gene",
            "entity_name": "COL12A1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24334604",
                "24334769",
                "21670218"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ullrich congenital muscular dystrophy 2, 616470",
                "Bethlem myopathy 2, 616471"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2190",
                "gene_name": "collagen type XIII alpha 1 chain",
                "omim_gene": [
                    "120350"
                ],
                "alias_name": null,
                "gene_symbol": "COL13A1",
                "hgnc_symbol": "COL13A1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:71561644-71724031",
                            "ensembl_id": "ENSG00000197467"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:69801931-69964275",
                            "ensembl_id": "ENSG00000197467"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1988-08-05"
            },
            "entity_type": "gene",
            "entity_name": "COL13A1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31081514",
                "28369367",
                "20844119"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Myasthenic syndrome, congenital, 19, OMIM:616720",
                "Congenital myasthenic syndrome 19, MONDO:0014745"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CL-L1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2220",
                "gene_name": "collectin subfamily member 10",
                "omim_gene": [
                    "607620"
                ],
                "alias_name": null,
                "gene_symbol": "COLEC10",
                "hgnc_symbol": "COLEC10",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "8:120007691-120118821",
                            "ensembl_id": "ENSG00000184374"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "8:118995452-119106582",
                            "ensembl_id": "ENSG00000184374"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-04-11"
            },
            "entity_type": "gene",
            "entity_name": "COLEC10",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28301481",
                "34740859"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "3MC syndrome 3, MONDO:0009554",
                "3MC syndrome 3, OMIM:248340"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "EAD"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2226",
                "gene_name": "collagen like tail subunit of asymmetric acetylcholinesterase",
                "omim_gene": [
                    "603033"
                ],
                "alias_name": [
                    "single strand of homotrimeric collagen-like tail subunit of asymmetric acetylcholinesterase",
                    "collagenic tail of endplate acetylcholinesterase",
                    "AChE Q subunit",
                    "acetylcholinesterase-associated collagen"
                ],
                "gene_symbol": "COLQ",
                "hgnc_symbol": "COLQ",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:15491640-15563258",
                            "ensembl_id": "ENSG00000206561"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:15450133-15521751",
                            "ensembl_id": "ENSG00000206561"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-09-14"
            },
            "entity_type": "gene",
            "entity_name": "COLQ",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "9689136",
                "9758617",
                "11865139",
                "32978031",
                "31831253"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Myasthenic syndrome, congenital, 5, MIM#603034"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA1283",
                    "VIP",
                    "K-CAP"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23228",
                "gene_name": "C3 and PZP like, alpha-2-macroglobulin domain containing 8",
                "omim_gene": [
                    "608841"
                ],
                "alias_name": null,
                "gene_symbol": "CPAMD8",
                "hgnc_symbol": "CPAMD8",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:17003758-17137625",
                            "ensembl_id": "ENSG00000160111"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:16892947-17026815",
                            "ensembl_id": "ENSG00000160111"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-04-30"
            },
            "entity_type": "gene",
            "entity_name": "CPAMD8",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "32274568"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Anterior segment dysgenesis 8, MIM# 617319"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RAIDD"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2340",
                "gene_name": "CASP2 and RIPK1 domain containing adaptor with death domain",
                "omim_gene": [
                    "603454"
                ],
                "alias_name": [
                    "RIP-associated ICH1/CED3-homologous protein with death domain"
                ],
                "gene_symbol": "CRADD",
                "hgnc_symbol": "CRADD",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:94071151-94288616",
                            "ensembl_id": "ENSG00000169372"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:93677375-93894840",
                            "ensembl_id": "ENSG00000169372"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-05-07"
            },
            "entity_type": "gene",
            "entity_name": "CRADD",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27773430"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Mental retardation, autosomal recessive 34, with variant lissencephaly, MIM# 614499"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "OASIS"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18856",
                "gene_name": "cAMP responsive element binding protein 3 like 1",
                "omim_gene": [
                    "616215"
                ],
                "alias_name": [
                    "BBF-2 homolog (drosophila)"
                ],
                "gene_symbol": "CREB3L1",
                "hgnc_symbol": "CREB3L1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:46299212-46342972",
                            "ensembl_id": "ENSG00000157613"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:46277661-46321422",
                            "ensembl_id": "ENSG00000157613"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-12-09"
            },
            "entity_type": "gene",
            "entity_name": "CREB3L1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24079343",
                "28817112",
                "29936144",
                "30657919"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Osteogenesis imperfecta, type XVI, 616229"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14630",
                "gene_name": "cysteine rich with EGF like domains 1",
                "omim_gene": [
                    "607170"
                ],
                "alias_name": null,
                "gene_symbol": "CRELD1",
                "hgnc_symbol": "CRELD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:9975506-9987097",
                            "ensembl_id": "ENSG00000163703"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:9933822-9945413",
                            "ensembl_id": "ENSG00000163703"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-02-16"
            },
            "entity_type": "gene",
            "entity_name": "CRELD1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22740159"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Atrioventricular septal defect, partial, with heterotaxy syndrome 606217"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HSPC139"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14312",
                "gene_name": "CXXC repeat containing interactor of PDZ3 domain",
                "omim_gene": [
                    "604594"
                ],
                "alias_name": null,
                "gene_symbol": "CRIPT",
                "hgnc_symbol": "CRIPT",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:46843555-46852881",
                            "ensembl_id": "ENSG00000119878"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:46616416-46625742",
                            "ensembl_id": "ENSG00000119878"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-06-22"
            },
            "entity_type": "gene",
            "entity_name": "CRIPT",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24389050",
                "27250922",
                "37013901",
                "36630262"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Short stature with microcephaly and distinctive facies (MIM#615789)",
                "Rothmund-Thomson syndrome MONDO:0010002"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2481",
                "gene_name": "cystatin A",
                "omim_gene": [
                    "184600"
                ],
                "alias_name": [
                    "stefin A"
                ],
                "gene_symbol": "CSTA",
                "hgnc_symbol": "CSTA",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:122044091-122060819",
                            "ensembl_id": "ENSG00000121552"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:122325244-122341972",
                            "ensembl_id": "ENSG00000121552"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1990-02-06"
            },
            "entity_type": "gene",
            "entity_name": "CSTA",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Peeling skin syndrome 4, MIM# 607936"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FCP1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2498",
                "gene_name": "CTD phosphatase subunit 1",
                "omim_gene": [
                    "604927"
                ],
                "alias_name": null,
                "gene_symbol": "CTDP1",
                "hgnc_symbol": "CTDP1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "18:77439801-77514510",
                            "ensembl_id": "ENSG00000060069"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "18:79679801-79756623",
                            "ensembl_id": "ENSG00000060069"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-02-09"
            },
            "entity_type": "gene",
            "entity_name": "CTDP1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20301787",
                "14517542",
                "24690360",
                "29174527",
                "25529582"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Congenital cataracts, facial dysmorphism, and neuropathy, MIM# 604168"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [
                "deep intronic",
                "founder"
            ],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0384",
                    "p120",
                    "p120cas",
                    "p120ctn"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2515",
                "gene_name": "catenin delta 1",
                "omim_gene": [
                    "601045"
                ],
                "alias_name": null,
                "gene_symbol": "CTNND1",
                "hgnc_symbol": "CTNND1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:57520715-57587018",
                            "ensembl_id": "ENSG00000198561"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:57753243-57819546",
                            "ensembl_id": "ENSG00000198561"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-09-18"
            },
            "entity_type": "gene",
            "entity_name": "CTNND1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28301459",
                "32196547"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Blepharocheilodontic syndrome 2, MIM# 617681"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "NCS2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28005",
                "gene_name": "cytosolic thiouridylase subunit 2",
                "omim_gene": [
                    "617057"
                ],
                "alias_name": null,
                "gene_symbol": "CTU2",
                "hgnc_symbol": "CTU2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "16:88772871-88781794",
                            "ensembl_id": "ENSG00000174177"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "16:88706463-88715386",
                            "ensembl_id": "ENSG00000174177"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2009-08-19"
            },
            "entity_type": "gene",
            "entity_name": "CTU2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27480277",
                "26633546"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome, MIM#618142"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0293",
                    "CDP2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19347",
                "gene_name": "cut like homeobox 2",
                "omim_gene": [
                    "610648"
                ],
                "alias_name": null,
                "gene_symbol": "CUX2",
                "hgnc_symbol": "CUX2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:111471828-111788358",
                            "ensembl_id": "ENSG00000111249"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:111034024-111350554",
                            "ensembl_id": "ENSG00000111249"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-11-07"
            },
            "entity_type": "gene",
            "entity_name": "CUX2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29630738",
                "29795476"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Epileptic encephalopathy, early infantile, 67, MIM#618141"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2873",
                "gene_name": "cytochrome b5 reductase 3",
                "omim_gene": [
                    "613213"
                ],
                "alias_name": [
                    "NADH-cytochrome b5 reductase 3"
                ],
                "gene_symbol": "CYB5R3",
                "hgnc_symbol": "CYB5R3",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "22:43013846-43045574",
                            "ensembl_id": "ENSG00000100243"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "22:42617840-42649568",
                            "ensembl_id": "ENSG00000100243"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-07-13"
            },
            "entity_type": "gene",
            "entity_name": "CYB5R3",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Methaemoglobinemia, type II, MIM# 250800"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "P450RAI-2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20581",
                "gene_name": "cytochrome P450 family 26 subfamily B member 1",
                "omim_gene": [
                    "605207"
                ],
                "alias_name": null,
                "gene_symbol": "CYP26B1",
                "hgnc_symbol": "CYP26B1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "2:72356367-72375167",
                            "ensembl_id": "ENSG00000003137"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "2:72129238-72148038",
                            "ensembl_id": "ENSG00000003137"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-01-26"
            },
            "entity_type": "gene",
            "entity_name": "CYP26B1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27410456",
                "22019272"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, MIM# 614416"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ39501"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26820",
                "gene_name": "cytochrome P450 family 4 subfamily F member 22",
                "omim_gene": [
                    "611495"
                ],
                "alias_name": null,
                "gene_symbol": "CYP4F22",
                "hgnc_symbol": "CYP4F22",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:15619304-15663128",
                            "ensembl_id": "ENSG00000171954"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:15508493-15552317",
                            "ensembl_id": "ENSG00000171954"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2007-05-18"
            },
            "entity_type": "gene",
            "entity_name": "CYP4F22",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ichthyosis, congenital, autosomal recessive 5, MIM# 604777"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "IGDCC1",
                    "NTN1R1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2701",
                "gene_name": "DCC netrin 1 receptor",
                "omim_gene": [
                    "120470"
                ],
                "alias_name": [
                    "immunoglobulin superfamily, DCC subclass, member 1"
                ],
                "gene_symbol": "DCC",
                "hgnc_symbol": "DCC",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "18:49866542-51057784",
                            "ensembl_id": "ENSG00000187323"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "18:52340172-53535903",
                            "ensembl_id": "ENSG00000187323"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1990-05-25"
            },
            "entity_type": "gene",
            "entity_name": "DCC",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "20431009",
                "31697046",
                "21242494",
                "28250454",
                "28250456"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Mirror movements 1 and/or agenesis of the corpus callosum, OMIM #157600",
                "Gaze palsy, familial horizontal, with progressive scoliosis, 2,OMIM # 617542"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RU2",
                    "KIAA1154",
                    "DCDC2A",
                    "NPHP19"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18141",
                "gene_name": "doublecortin domain containing 2",
                "omim_gene": [
                    "605755"
                ],
                "alias_name": null,
                "gene_symbol": "DCDC2",
                "hgnc_symbol": "DCDC2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "6:24171984-24358280",
                            "ensembl_id": "ENSG00000146038"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "6:24171756-24358052",
                            "ensembl_id": "ENSG00000146038"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-05-20"
            },
            "entity_type": "gene",
            "entity_name": "DCDC2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27469900",
                "25557784",
                "31821705"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "KidGen_CilioNephronop v38.1.0"
            ],
            "phenotypes": [
                "Nephronophthisis 19, MIM# 616217"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DKFZP564B1023",
                    "ZNHIT5"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:25360",
                "gene_name": "DEAD-box helicase 59",
                "omim_gene": [
                    "615464"
                ],
                "alias_name": null,
                "gene_symbol": "DDX59",
                "hgnc_symbol": "DDX59",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:200593024-200639097",
                            "ensembl_id": "ENSG00000118197"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:200623896-200669969",
                            "ensembl_id": "ENSG00000118197"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-02-22"
            },
            "entity_type": "gene",
            "entity_name": "DDX59",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29127725",
                "23972372",
                "28711741"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert Review",
                "KidGen_CilioNephronop v38.1.0"
            ],
            "phenotypes": [
                "Orofaciodigital syndrome V, MONDO:0008267",
                "Orofaciodigital syndrome V, OMIM:174300"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "RCK"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2747",
                "gene_name": "DEAD-box helicase 6",
                "omim_gene": [
                    "600326"
                ],
                "alias_name": null,
                "gene_symbol": "DDX6",
                "hgnc_symbol": "DDX6",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:118620034-118661858",
                            "ensembl_id": "ENSG00000110367"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:118747766-118791149",
                            "ensembl_id": "ENSG00000110367"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-09-14"
            },
            "entity_type": "gene",
            "entity_name": "DDX6",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "31422817"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Literature"
            ],
            "phenotypes": [
                "Intellectual developmental disorder with impaired language and dysmorphic facies, MIM#618653"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA1091",
                    "FLJ22354",
                    "FLJ33829",
                    "FLJ43455"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19344",
                "gene_name": "DENN domain containing 5A",
                "omim_gene": [
                    "617278"
                ],
                "alias_name": null,
                "gene_symbol": "DENND5A",
                "hgnc_symbol": "DENND5A",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:9160372-9286937",
                            "ensembl_id": "ENSG00000184014"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:9138825-9265390",
                            "ensembl_id": "ENSG00000184014"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2008-08-14"
            },
            "entity_type": "gene",
            "entity_name": "DENND5A",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27431290",
                "27866705",
                "32705489"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Developmental and epileptic encephalopathy, 49, MONDO:0015002",
                "Developmental and epileptic encephalopathy 49, OMIM:617281"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "HDS",
                    "FLJ13102",
                    "DS",
                    "RP59"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20603",
                "gene_name": "dehydrodolichyl diphosphate synthase subunit",
                "omim_gene": [
                    "608172"
                ],
                "alias_name": null,
                "gene_symbol": "DHDDS",
                "hgnc_symbol": "DHDDS",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:26758773-26797785",
                            "ensembl_id": "ENSG00000117682"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:26432282-26471294",
                            "ensembl_id": "ENSG00000117682"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-05-22"
            },
            "entity_type": "gene",
            "entity_name": "DHDDS",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29100083"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Developmental delay and seizures with or without movement abnormalities, MIM#617836"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA1630",
                    "MGC3090",
                    "DKFZP762M115",
                    "CMT2Q"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23537",
                "gene_name": "dehydrogenase E1 and transketolase domain containing 1",
                "omim_gene": [
                    "614984"
                ],
                "alias_name": null,
                "gene_symbol": "DHTKD1",
                "hgnc_symbol": "DHTKD1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:12110971-12165224",
                            "ensembl_id": "ENSG00000181192"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:12068972-12123225",
                            "ensembl_id": "ENSG00000181192"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-11-24"
            },
            "entity_type": "gene",
            "entity_name": "DHTKD1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23141294",
                "29661920",
                "28902413",
                "27604308",
                "23141293",
                "25860818"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "2-aminoadipic 2-oxoadipic aciduria MIM#204750",
                "Disorders of histidine, tryptophan or lysine metabolism"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA0890",
                    "FLJ11214"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:16716",
                "gene_name": "DExH-box helicase 30",
                "omim_gene": [
                    "616423"
                ],
                "alias_name": null,
                "gene_symbol": "DHX30",
                "hgnc_symbol": "DHX30",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:47844399-47891685",
                            "ensembl_id": "ENSG00000132153"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:47802909-47850195",
                            "ensembl_id": "ENSG00000132153"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-06-13"
            },
            "entity_type": "gene",
            "entity_name": "DHX30",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29100085"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Neurodevelopmental disorder with severe motor impairment and absent language, MIM#617804"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "hDIA1",
                    "LFHL1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2876",
                "gene_name": "diaphanous related formin 1",
                "omim_gene": [
                    "602121"
                ],
                "alias_name": null,
                "gene_symbol": "DIAPH1",
                "hgnc_symbol": "DIAPH1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "5:140894583-140998622",
                            "ensembl_id": "ENSG00000131504"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "5:141515016-141619055",
                            "ensembl_id": "ENSG00000131504"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1998-03-17"
            },
            "entity_type": "gene",
            "entity_name": "DIAPH1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24781755, 26463574, 33662367, 36212620, 39076976, 39120629"
            ],
            "evidence": [
                "Literature",
                "Expert Review Green"
            ],
            "phenotypes": [
                "Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome, MONDO:0014714"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DISPA",
                    "MGC13130",
                    "DKFZP434I0428",
                    "MGC16796"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19711",
                "gene_name": "dispatched RND transporter family member 1",
                "omim_gene": [
                    "607502"
                ],
                "alias_name": null,
                "gene_symbol": "DISP1",
                "hgnc_symbol": "DISP1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:222988406-223179337",
                            "ensembl_id": "ENSG00000154309"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:222872271-223005995",
                            "ensembl_id": "ENSG00000154309"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-12-12"
            },
            "entity_type": "gene",
            "entity_name": "DISP1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27363716",
                "19184110",
                "26748417",
                "23542665",
                "38529886"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Holoprosencephaly 10, MIM# 621143"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "PSD-95",
                    "PSD95",
                    "SAP90",
                    "SAP-90"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2903",
                "gene_name": "discs large MAGUK scaffold protein 4",
                "omim_gene": [
                    "602887"
                ],
                "alias_name": null,
                "gene_symbol": "DLG4",
                "hgnc_symbol": "DLG4",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:7093209-7123021",
                            "ensembl_id": "ENSG00000132535"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:7189890-7219702",
                            "ensembl_id": "ENSG00000132535"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1995-11-07"
            },
            "entity_type": "gene",
            "entity_name": "DLG4",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "27479843",
                "25123844",
                "19617690",
                "29460436",
                "23020937",
                "28135719",
                "33597769"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Intellectual developmental disorder 62, MIM#\t618793"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2918",
                "gene_name": "distal-less homeobox 5",
                "omim_gene": [
                    "600028"
                ],
                "alias_name": null,
                "gene_symbol": "DLX5",
                "hgnc_symbol": "DLX5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:96649704-96654409",
                            "ensembl_id": "ENSG00000105880"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:97020392-97025097",
                            "ensembl_id": "ENSG00000105880"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1994-05-24"
            },
            "entity_type": "gene",
            "entity_name": "DLX5",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "22121204",
                "24496061",
                "25196357",
                "20534536",
                "12112878",
                "41760400"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Split-hand/foot malformation 1 with sensorineural hearing loss MIM#220600",
                "Split-hand/foot malformation 1 MIM#183600"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ10563",
                    "KTU",
                    "PF13",
                    "CILD10"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:20188",
                "gene_name": "dynein axonemal assembly factor 2",
                "omim_gene": [
                    "612517"
                ],
                "alias_name": [
                    "kintoun"
                ],
                "gene_symbol": "DNAAF2",
                "hgnc_symbol": "DNAAF2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:50091892-50101948",
                            "ensembl_id": "ENSG00000165506"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:49625174-49635230",
                            "ensembl_id": "ENSG00000165506"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2011-06-09"
            },
            "entity_type": "gene",
            "entity_name": "DNAAF2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "19052621",
                "31107948"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Ciliary dyskinesia, primary, 10, 612518"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "FLJ20397",
                    "FLJ31671",
                    "FLJ39381",
                    "FLJ25564",
                    "CILD18"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:26013",
                "gene_name": "dynein axonemal assembly factor 5",
                "omim_gene": [
                    "614864"
                ],
                "alias_name": null,
                "gene_symbol": "DNAAF5",
                "hgnc_symbol": "DNAAF5",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "7:766338-829190",
                            "ensembl_id": "ENSG00000164818"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "7:726701-786475",
                            "ensembl_id": "ENSG00000164818"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2014-12-05"
            },
            "entity_type": "gene",
            "entity_name": "DNAAF5",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23040496",
                "29363216",
                "25232951"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Primary ciliary dyskinesia 18, MONDO:0013940",
                "Ciliary dyskinesia, primary, 18, OMIM:614874"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "CILD9",
                    "DIC2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:18744",
                "gene_name": "dynein axonemal intermediate chain 2",
                "omim_gene": [
                    "605483"
                ],
                "alias_name": [
                    "dynein intermediate chain 2"
                ],
                "gene_symbol": "DNAI2",
                "hgnc_symbol": "DNAI2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:72270386-72311023",
                            "ensembl_id": "ENSG00000171595"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:74274247-74314884",
                            "ensembl_id": "ENSG00000171595"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2002-06-12"
            },
            "entity_type": "gene",
            "entity_name": "DNAI2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "18950741",
                "23261302"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Ciliary dyskinesia, primary, 9, with or without situs inversus, MIM#612444"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "EDJ",
                    "HEDJ",
                    "ERdj3"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:14889",
                "gene_name": "DnaJ heat shock protein family (Hsp40) member B11",
                "omim_gene": [
                    "611341"
                ],
                "alias_name": null,
                "gene_symbol": "DNAJB11",
                "hgnc_symbol": "DNAJB11",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:186285192-186315061",
                            "ensembl_id": "ENSG00000090520"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:186567403-186585800",
                            "ensembl_id": "ENSG00000090520"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2001-03-09"
            },
            "entity_type": "gene",
            "entity_name": "DNAJB11",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29706351",
                "29777155",
                "33129895",
                "34177435"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Polycystic kidney disease 6 with or without polycystic liver disease, 618061"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic (but BIALLELIC mutations cause a more SEVERE disease form), autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "JDP1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:28908",
                "gene_name": "DnaJ heat shock protein family (Hsp40) member C12",
                "omim_gene": [
                    "606060"
                ],
                "alias_name": [
                    "J domain protein 1"
                ],
                "gene_symbol": "DNAJC12",
                "hgnc_symbol": "DNAJC12",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "10:69556427-69597924",
                            "ensembl_id": "ENSG00000108176"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "10:67796665-67838166",
                            "ensembl_id": "ENSG00000108176"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2004-04-15"
            },
            "entity_type": "gene",
            "entity_name": "DNAJC12",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert list"
            ],
            "phenotypes": [
                "Hyperphenylalaninemia, mild, non-BH4-deficient, MIM#617384"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "TIMM14",
                    "Tim14",
                    "Pam18"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:30528",
                "gene_name": "DnaJ heat shock protein family (Hsp40) member C19",
                "omim_gene": [
                    "608977"
                ],
                "alias_name": null,
                "gene_symbol": "DNAJC19",
                "hgnc_symbol": "DNAJC19",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "3:180701497-180707562",
                            "ensembl_id": "ENSG00000205981"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "3:180983709-180989774",
                            "ensembl_id": "ENSG00000205981"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-07-28"
            },
            "entity_type": "gene",
            "entity_name": "DNAJC19",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "16055927",
                "17244376",
                "22797137"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "3-methylglutaconic aciduria, type V 610198"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC12435",
                    "1700010H15RiK",
                    "CILD16"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:23247",
                "gene_name": "dynein axonemal light chain 1",
                "omim_gene": [
                    "610062"
                ],
                "alias_name": null,
                "gene_symbol": "DNAL1",
                "hgnc_symbol": "DNAL1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "14:74111578-74170435",
                            "ensembl_id": "ENSG00000119661"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "14:73644875-73703732",
                            "ensembl_id": "ENSG00000119661"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2006-09-04"
            },
            "entity_type": "gene",
            "entity_name": "DNAL1",
            "confidence_level": "2",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "21496787"
            ],
            "evidence": [
                "Expert Review Amber",
                "Genomics England PanelApp",
                "Victorian Clinical Genetics Services"
            ],
            "phenotypes": [
                "Ciliary dyskinesia, primary, 16, MIM# 614017"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2972",
                "gene_name": "dynamin 1",
                "omim_gene": [
                    "602377"
                ],
                "alias_name": null,
                "gene_symbol": "DNM1",
                "hgnc_symbol": "DNM1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:130965658-131017527",
                            "ensembl_id": "ENSG00000106976"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:128191655-128255248",
                            "ensembl_id": "ENSG00000106976"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1992-07-09"
            },
            "entity_type": "gene",
            "entity_name": "DNM1",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25262651",
                "27066543",
                "33372033",
                "34172529"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Developmental and epileptic encephalopathy 31A, autosomal dominant, MIM# 616346",
                "Developmental and epileptic encephalopathy 31B, autosomal recessive, MIM# 620352"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DRP1",
                    "DVLP",
                    "HDYNIV",
                    "DYMPLE",
                    "VPS1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2973",
                "gene_name": "dynamin 1 like",
                "omim_gene": [
                    "603850"
                ],
                "alias_name": null,
                "gene_symbol": "DNM1L",
                "hgnc_symbol": "DNM1L",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "12:32832134-32898486",
                            "ensembl_id": "ENSG00000087470"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "12:32679200-32745650",
                            "ensembl_id": "ENSG00000087470"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-04-12"
            },
            "entity_type": "gene",
            "entity_name": "DNM1L",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "Other",
            "publications": [
                "31587467, 27145208, 26604000, 27301544, 26931468, 33718295, 30109270, 26825290, 27328748"
            ],
            "evidence": [
                "Literature",
                "ClinGen",
                "Expert Review Green"
            ],
            "phenotypes": [
                "Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, MONDO:0013726"
            ],
            "mode_of_inheritance": "BOTH monoallelic and biallelic, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "DYNII",
                    "DYN2",
                    "CMTDIB",
                    "CMTDI1",
                    "DI-CMTB",
                    "CMT2M"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2974",
                "gene_name": "dynamin 2",
                "omim_gene": [
                    "602378"
                ],
                "alias_name": [
                    "dynamin II",
                    "cytoskeletal protein"
                ],
                "gene_symbol": "DNM2",
                "hgnc_symbol": "DNM2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "19:10828755-10944164",
                            "ensembl_id": "ENSG00000079805"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "19:10718079-10833488",
                            "ensembl_id": "ENSG00000079805"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1996-10-11"
            },
            "entity_type": "gene",
            "entity_name": "DNM2",
            "confidence_level": "1",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "PMID: 30208955"
            ],
            "evidence": [
                "Expert Review Red",
                "Genomics England PanelApp",
                "Expert Review"
            ],
            "phenotypes": [
                "Lethal congenital contracture syndrome 5, MIM#615368"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "KIAA1771",
                    "ZIR2"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:19190",
                "gene_name": "dedicator of cytokinesis 7",
                "omim_gene": [
                    "615730"
                ],
                "alias_name": null,
                "gene_symbol": "DOCK7",
                "hgnc_symbol": "DOCK7",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "1:62920399-63153969",
                            "ensembl_id": "ENSG00000116641"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "1:62454298-62688368",
                            "ensembl_id": "ENSG00000116641"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-11-19"
            },
            "entity_type": "gene",
            "entity_name": "DOCK7",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "24814191",
                "30771731",
                "30807358"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Developmental and epileptic encephalopathy 23 MIM#615859"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "B17",
                    "C2TA",
                    "DKFZP434M035"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:2993",
                "gene_name": "downstream neighbor of SON",
                "omim_gene": [
                    "611428"
                ],
                "alias_name": null,
                "gene_symbol": "DONSON",
                "hgnc_symbol": "DONSON",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "21:34931848-34961014",
                            "ensembl_id": "ENSG00000159147"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "21:33559542-33588708",
                            "ensembl_id": "ENSG00000159147"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2000-02-18"
            },
            "entity_type": "gene",
            "entity_name": "DONSON",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "28191891",
                "28630177",
                "28191891"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Expert Review"
            ],
            "phenotypes": [
                "Microcephaly, short stature, and limb abnormalities, MIM# 617604",
                "Microcephaly-micromelia syndrome, MIM# 251230",
                "MONDO:0009619"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "ubi-d4",
                    "BAF45d"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:9964",
                "gene_name": "double PHD fingers 2",
                "omim_gene": [
                    "601671"
                ],
                "alias_name": null,
                "gene_symbol": "DPF2",
                "hgnc_symbol": "DPF2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "11:65101225-65120720",
                            "ensembl_id": "ENSG00000133884"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "11:65333754-65353249",
                            "ensembl_id": "ENSG00000133884"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2003-10-08"
            },
            "entity_type": "gene",
            "entity_name": "DPF2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "29429572",
                "31706665"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp"
            ],
            "phenotypes": [
                "Coffin-Siris syndrome 7, MIM#618027"
            ],
            "mode_of_inheritance": "MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "OVCA1"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3003",
                "gene_name": "diphthamide biosynthesis 1",
                "omim_gene": [
                    "603527"
                ],
                "alias_name": [
                    "ovarian tumor suppressor candidate 1"
                ],
                "gene_symbol": "DPH1",
                "hgnc_symbol": "DPH1",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "17:1933404-1946724",
                            "ensembl_id": "ENSG00000108963"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "17:2030110-2043430",
                            "ensembl_id": "ENSG00000108963"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "2005-06-03"
            },
            "entity_type": "gene",
            "entity_name": "DPH1",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "25558065",
                "32732226",
                "30877278",
                "29362492"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Developmental delay with short stature, dysmorphic facial features, and sparse hair, OMIM:616901"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        },
        {
            "gene_data": {
                "alias": [
                    "MGC21559",
                    "MGC111193"
                ],
                "biotype": "protein_coding",
                "hgnc_id": "HGNC:3006",
                "gene_name": "dolichyl-phosphate mannosyltransferase subunit 2, regulatory",
                "omim_gene": [
                    "603564"
                ],
                "alias_name": [
                    "DPM synthase complex subunit"
                ],
                "gene_symbol": "DPM2",
                "hgnc_symbol": "DPM2",
                "hgnc_release": "2017-11-03",
                "ensembl_genes": {
                    "GRch37": {
                        "82": {
                            "location": "9:130697378-130700763",
                            "ensembl_id": "ENSG00000136908"
                        }
                    },
                    "GRch38": {
                        "90": {
                            "location": "9:127935099-127938484",
                            "ensembl_id": "ENSG00000136908"
                        }
                    }
                },
                "hgnc_date_symbol_changed": "1999-02-23"
            },
            "entity_type": "gene",
            "entity_name": "DPM2",
            "confidence_level": "3",
            "penetrance": null,
            "mode_of_pathogenicity": "",
            "publications": [
                "23109149",
                "33129689"
            ],
            "evidence": [
                "Expert Review Green",
                "Genomics England PanelApp",
                "Genetic Health Queensland"
            ],
            "phenotypes": [
                "Congenital disorder of glycosylation, type Iu, 615042"
            ],
            "mode_of_inheritance": "BIALLELIC, autosomal or pseudoautosomal",
            "tags": [],
            "panel": {
                "id": 3763,
                "hash_id": null,
                "name": "Fetal anomalies",
                "disease_group": "",
                "disease_sub_group": "",
                "description": "The Fetal Anomalies panel is intended to be used in the prenatal setting where multidisciplinary review (e.g. clinical geneticist, maternal-fetal medicine specialist, genetic pathologist, clinical scientist, paediatric subspecialist) considers a monogenic disorder is likely based on the presenting clinical features. It can also be used to direct analysis as part of fetal molecular autopsy.\r\n\r\nCommon example clinical indications include:\r\n• Multiple structural anomalies\r\n• Suspected skeletal dysplasias (IUGR of placental origin should be excluded)\r\n• Large echogenic kidneys (in the absence of ureter or bladder outlet obstruction)\r\n• Major CNS abnormalities (excluding neural tube defects)\r\n• Multiple contractures (excluding isolated bilateral talipes)\r\n• Nuchal translucency of greater than 6.5mm plus another anomaly (that can include a minor finding)\r\n• Isolated non-immune fetal hydrops (detected at or after the routine 18-20-week scan in the second or third trimesters), defined as fluid/oedema in at least two compartments (e.g. skin, pleural, pericardial or ascites).\r\n\r\nChromosomal microarray is strongly recommended prior to genomic testing.\r\n\r\nMore targeted panels such as Hydrops, Ventriculomegaly, Arhthrogryposis are also available.\r\n\r\nThis panel is based on a targeted virtual gene panel for developmental disorders developed by the PAGE (Prenatal Assessment of Genomes and Exomes) group, Lord et al 2019, and subsequent refinement by Genomics England/NHS Genomic Medicine Service. It incorporates panels used in the Melbourne Genomics Perinatal Molecular Autopsy study.",
                "status": "public",
                "version": "1.558",
                "version_created": "2026-04-07T13:44:14.990434+10:00",
                "relevant_disorders": [],
                "stats": {
                    "number_of_genes": 2207,
                    "number_of_strs": 3,
                    "number_of_regions": 6
                },
                "types": [
                    {
                        "name": "Victorian Clinical Genetics Services",
                        "slug": "victorian-clinical-genetics-services",
                        "description": "Panel used by VCGS."
                    },
                    {
                        "name": "Rare Disease",
                        "slug": "rare-disease",
                        "description": "Rare disease panels"
                    }
                ],
                "child_panel_ids": []
            },
            "transcript": null
        }
    ]
}